Catalogue preview · final packaging and presentation may vary if stockedFive choices across your ballotUse votes only for compounds you would consider ordering
One vote per compoundEach candidate can be selected once on this browser
Flexible interest signalRemove or reassign a vote whenever you like
SS-31
SS-31 is the research name for elamipretide, a mitochondria-targeting tetrapeptide that associates with cardiolipin in the inner mitochondrial membrane. It is studied for effects on membrane organization, electron transport, and mitochondrial stress.
Loading your saved choices…
SS-31 is currently being evaluated through customer voting and is not available to order. Final product specifications and batch documentation will be published only if it joins the catalogue.
This page records catalogue interest only. If SS-31 is selected for supply, Puffin will publish the confirmed format, batch documentation, and laboratory preparation information on the product listing.
Storage and handling requirements depend on the final supplied format. Confirmed instructions will be provided with the batch details if this candidate is added to the catalogue.
Understanding SS-31
Explore the science, research focus, and key information behind this compound.
What is SS-31?+
Its mitochondria-targeting design makes SS-31 a focused option for membrane and cardiolipin research.
What Researchers Study+
Researchers examine Cardiolipin interaction, Mitochondrial-membrane models, and Oxidative-stress response.
How SS-31 Works+
Cardiolipin helps organize proteins that produce cellular energy. Elamipretide is proposed to stabilize cardiolipin-protein interactions and reduce inefficient electron transfer under stress. In plain language, it targets the membrane machinery around energy production rather than acting as a general antioxidant sponge.
Research at a Glance+
One elamipretide product has accelerated approval. Forzinity is approved in the United States for a specific Barth-syndrome population under accelerated approval. Continued approval can depend on verification of clinical benefit; the label defines the actual product and indication. Read the official FDA label. Cardiolipin is the central research target. Biophysical and preclinical studies support interaction with inner-membrane cardiolipin and downstream effects on mitochondrial organization. Results vary with disease model and endpoint. Approval does not turn every SS-31 vial into Forzinity. The regulated product has defined formulation, potency, manufacturing, dose, and labelling. The shared active name does not establish pharmaceutical equivalence for research material.
If this candidate is added to the catalogue, it would be offered for controlled laboratory research only. It is not for human consumption and is not represented as a medicine, treatment, supplement, or substitute for an approved product.